Home LiteratureArticle Details
PMID: 3771749 Published · ppublish English Journal Article

Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome.

Journal of clinical microbiology ·Vol. 24 ·No. 4 ·1986-10-00 ·Pages 600-6

Radetsky M, Wheeler RC, Roe MH, Todd JK

Abstract

There is no ideal laboratory procedure or culture medium in current use for susceptibility testing of pathogenic yeasts. Six candidate growth media (RPMI 1640 with L-glutamine, yeast nitrogen base, Casamino Acids medium, Mueller-Hinton broth, Sabouraud dextrose broth, and minimum essential medium-Eagle salts) were screened by spectrophotometric absorbance for nucleic acid and protein. From these, two media were selected: a chemically defined growth medium (RPMI 1640 with L-glutamine) and a chemically complex medium (Casamino Acids). MICs of four antifungal agents (5-fluorocytosine, miconazole, ketoconazole, and amphotericin B) for 84 clinical isolates of various Candida species were then determined with both media in agar dilution and microtiter broth dilution systems. The resultant MICs were correlated with clinical outcome for those isolates obtained from patients treated with single antifungal agents, and susceptibility cut points were calculated. Derived MIC cut points for susceptibility were validated in a murine model of systemic candidiasis. RPMI 1640 with L-glutamine was found to have the lowest absorbance values for both nucleic acid and protein, while Casamino Acids medium was highest in both categories. We found that RPMI 1640 with L-glutamine was superior to Casamino Acids medium in the yield of MICs which correlated with actual clinical and animal outcome data. While there were no significant differences in MICs when RPMI 1640 medium was used, the microtiter broth dilution technique was superior to agar dilution in efficiency and ease of performance. We conclude that a microtiter broth system containing RPMI 1640 medium with L-glutamine is a simple, precise, and economical technique for susceptibility testing of pathogenic Candida species. We also suggest that the validation of susceptibility cut points with patient and animal outcome data make this microtiter broth system a preferential method for yeast susceptibility testing.

MeSH Terms
Amphotericin B/pharmacology,therapeutic use Animals Candida/drug effects Candidiasis/drug therapy Culture Media Flucytosine/pharmacology Humans Ketoconazole/pharmacology,therapeutic use Mice Miconazole/pharmacology,therapeutic use Microbial Sensitivity Tests
Chemicals
Culture Media Miconazole Amphotericin B Flucytosine Ketoconazole
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Radetsky M
Wheeler R C
Roe M H
Todd J K
References (34)
34 references, click to expand
  1. The action of miconazole of the growth of Candida albicans.
    Sabouraudia. 1975 Mar;13 Pt 1:63-73 PMID: 1091999
  2. Fungistatic activity, uptake and incorporation of 5-fluorocytosine in Candida albicans, as influenced by pyrimidines and purines. I. Reversal experiments.
    Pathol Microbiol (Basel). 1973;39(2):148-59 PMID: 4575668
  3. Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester.
    J Infect Dis. 1976 Oct;134(4):336-41 PMID: 789787
  4. Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.
    Antimicrob Agents Chemother. 1976 Oct;10(4):721-8 PMID: 984806
  5. Miconazole-resistant Candida.
    Lancet. 1978 Jan 7;1(8054):50-1 PMID: 74535
  6. Factors influencing the susceptibility of Candida albicans to the polyenoic antibiotics nystatin and amphotericin B.
    J Gen Microbiol. 1978 Feb;104(2):325-33 PMID: 24676
  7. Pathogenicity in mice of strains of Candida albicans with different in vitro sensitivity to 5-fluorocytosine.
    Scand J Infect Dis. 1978;10(1):87-90 PMID: 345424
  8. Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods.
    Antimicrob Agents Chemother. 1978 Feb;13(2):249-54 PMID: 646347
  9. Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy.
    Ann Intern Med. 1978 Jul;89(1):91-106 PMID: 352220
  10. Disk agar diffusion susceptibility testing of yeasts.
    Antimicrob Agents Chemother. 1978 Oct;14(4):517-30 PMID: 568910
  11. Assay for yeast susceptibility to 5-fluorocytosine and amphotericin B in a frozen microtiter system.
    Am J Clin Pathol. 1979 Aug;72(2):194-8 PMID: 382827
  12. Tablet sensitivity testing on pathogenic fungi.
    J Clin Pathol. 1979 Jul;32(7):719-22 PMID: 500839
  13. Chronic mucocutaneous candidosis and other superficial and systemic mycoses successfully treated with ketoconazole.
    Rev Infect Dis. 1980 Jul-Aug;2(4):606-19 PMID: 6255540
  14. Hematogenous candida endophthalmitis in patients receiving parenteral hyperalimentation fluids.
    J Infect Dis. 1981 May;143(5):655-61 PMID: 6787141
  15. Heterogeneity of action of mechanisms among antimycotic imidazoles.
    Antimicrob Agents Chemother. 1981 Jul;20(1):71-4 PMID: 6269485
  16. Primary site of action of ketoconazole on Candida albicans.
    Antimicrob Agents Chemother. 1982 Jun;21(6):912-8 PMID: 6287929
  17. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States.
    Antimicrob Agents Chemother. 1982 Sep;22(3):482-7 PMID: 6753737
  18. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.
    Ann Intern Med. 1983 Jan;98(1):13-20 PMID: 6293361
  19. Neonatal systemic candidiasis: a failure to respond to intravenous miconazole in two neonates.
    Arch Dis Child. 1982 Nov;57(11):884-6 PMID: 7149766
  20. Systemic candidiasis: a study of 109 fatal cases.
    Pediatr Infect Dis. 1982 Jan-Feb;1(1):11-8 PMID: 7177889
  21. Effects of pH on the activity of ketoconazole against Candida albicans.
    Antimicrob Agents Chemother. 1983 Jan;23(1):105-7 PMID: 6299178
  22. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model.
    J Infect Dis. 1983 Jun;147(6):1070-7 PMID: 6343524
  23. Disseminated fungal infections in very low-birth-weight infants: clinical manifestations and epidemiology.
    Pediatrics. 1984 Feb;73(2):144-52 PMID: 6420764
  24. Azole resistance in Candida albicans.
    Sabouraudia. 1984;22(1):53-63 PMID: 6322363
  25. Oral candidiasis: pathogenesis and host defense.
    Rev Infect Dis. 1984 Jan-Feb;6(1):96-106 PMID: 6369482
  26. In vitro susceptibilities of sucrose-negative Candida tropicalis, Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole, and ketoconazole.
    J Clin Microbiol. 1984 Mar;19(3):412-6 PMID: 6325491
  27. Systemic candidiasis in cancer patients.
    Am J Med. 1984 Oct 30;77(4D):20-7 PMID: 6093530
  28. Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii.
    Ann Intern Med. 1985 Jan;102(1):67-8 PMID: 3966747
  29. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis.
    Rev Infect Dis. 1984 Nov-Dec;6(6):791-801 PMID: 6522917
  30. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis.
    Antimicrob Agents Chemother. 1985 Dec;28(6):751-5 PMID: 4083860
  31. Perspective on the management of catheter-related infections in cancer patients.
    Pediatr Infect Dis. 1986 Jan-Feb;5(1):6-11 PMID: 3945579
  32. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B.
    J Clin Microbiol. 1986 Feb;23(2):298-301 PMID: 3517051
  33. Problems in the diagnosis and treatment of systemic candidiasis.
    J Infect Dis. 1972 Feb;125(2):190-3 PMID: 5007556
  34. Laboratory tests of antifungal drugs.
    J Clin Pathol. 1975 Oct;28(10):767-74 PMID: 765359
Article Info
Journal
Journal of clinical microbiology
Abbr.
J Clin Microbiol
ISSN
0095-1137
Published
1986-10-00
Pages
600-6
Language
English
Region
United States
NLM ID
7505564
PMCID
PMC268979
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com